Interested in achieving your regulatory milestones faster? Join Quotient Sciences & Ensysce Biosciences for an exclusive customer case study lunch seminar during DCAT Week in NYC.

Presentation Overview

Many pharma and biotech companies are seeking new ways of making drug development more efficient and cost-effective in order to achieve their regulatory milestones faster. To meet this demand, the outsourcing services sector has scaled and grown, but in doing so, has become more siloed, with separate vendors each handling different activities – from medicinal chemistry, to preclinical studies, to clinical research, to product development and manufacturing. This separation has created a more complex approach to drug development for sponsor companies, where there is a distinct lack of communication between the multiple vendors working on a particular drug molecule, leading to delayed timelines, increased risk and higher costs.  

Quotient Sciences' Head of Early Development & Late-Stage Commercial, Dr. Sarah Stevens, will be joined by our customer Lynn Kirkpatrick, CEO of Ensysce Biosciences, to discuss the benefits of using Quotient Sciences integrated drug development platform, Translational Pharmaceutics® to accelerate their development timeline.  Translational Pharmaceutics® integrates drug substance, drug product, and clinical testing activities under a single program manager and single company to streamline drug development activities.

Hear Lynn's first hand experience working with Quotient Sciences and utilizing Translational Pharmaceutics for their PF14-MPAR program. She will touch on why Ensysce selected Quotient Sciences as their outsourcing partner, provide an overview of their project scope, and discuss how Translational Pharmaceutics was employed to help support their corporate goals. PF614-MPAR, which is currently in Phase 1, is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose.  Quotient Sciences has supported Ensysce by providing an integrated formulation development and phase 1 clinical study program for PF614. 

Here's what you'll learn:

• How the integration of drug substance, drug product, and clinical testing activities under one organization can create a more agile approach to pharmaceutical development and accelerate the path to IND 
• How drug product formulations and doses can be adjusted and manufactured in real-time, or in response to emerging human data
• Customer insight from Ensysce Biosciences about working with Quotient Sciences:
  • Why Ensysce Biosciences selected Quotient Scicences as their outsourcing partner for PF614-MPAR
  • How the Quotient Sciences Translational Pharmaceutics platform accelerated Ensysce Biosciences' drug development timeline
  • What Ensysce Biosciences hopes to achieve next through their partnership with Quotient Sciences

Featured Speakers

Lynn Kirkpatrick, CEO of Ensysce Biosciences
Lynn Kirkpatrick is the CEO of Ensysce Biosciences, a clinical-stage biotech company based in San Diego, CA. Her professional background is in medicinal chemistry, pharmacology, drug discovery and drug product development.  She has co-founded two start up companies in her career and has developed three targeted small molecule oncology drugs from discovery to the clinic. She has experience in both private and public companies raising funds from private, public and government sources.

Sarah Stevens, SVP and Head of Early Development & Late-Stage Commercial at Quotient Sciences
Dr. Sarah Stevens is Senior Vice President & Head of Early Development & Late Stage Commercial at Quotient Sciences, with oversight for all global sites and operational functions from early drug development programs through to late stage and commercial manufacturing.